<DOC>
	<DOCNO>NCT01808391</DOCNO>
	<brief_summary>This prospective , multicenter , historical control study . The present clinical study measure non-inferiority 12 month TLF rate compare historical control.The select historical control Xience V arm RESOLUTE All-Comer clinical study , study prospective , multicenter , randomize , two-arm , international , open-label study.The historical control angiographic follow 12 month , present clinical study , subject clinical follow-up conduct 12 month without pre-specified angiographic assessment prior 12 month clinical follow-up part analysis cohort . Out total 1200 patient , 900 patient ( clinical follow-up cohort ) include analysis cohort .</brief_summary>
	<brief_title>A Prospective Multicenter Post Approval Study Evaluate Long-term Safety Efficacy Resolute Integrity Japanese All-comers Patients With Coronary Artery Disease ( PROPEL )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patients age 20 year old . Patients symptomatic coronary disease . Patients clinical indication PCI stenting least one coronary lesion , visually confirm coronary angiography . Patients give inform consent participate clinical study sign inform consent form approve institutional review board study site index PCI . Patients agree undergo clinical followup procedure specify protocol clinical study . Patients 50 % occlusion stenosis visually confirm native coronary artery diameter 2.5 mm 3.5 mm coronary angiography anatomical structure suitable PCI use Resolute Integrity zotarolimuseluting stent . Patients age 85 year old . Patients cardiogenic shock . Patients pregnant possibly pregnant . Patients comply antiplatelet therapy specify clinical study . Patients schedule undergo elective surgery within 6 month postindex PCI . Patients history allergic reaction hypersensitivity zotarolimus , sirolimus , tacrolimus , everolimus , analogues derivative . Patients allergic reaction antiplatelet anticoagulant drug , heparin , aspirin , ticlopidine , clopidogrel , contrast agent , tolerate substance appropriate treatment give . Patients hypersensitivity cobalt , nickel , chrome , molybdenum , coat polymer ( e.g. , BioLinx ) contain material study device substance specifically contraindicate . Patients currently participate clinical study another drug medical device assessment primary endpoint study complete clinically interfere endpoint clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Heart disease</keyword>
	<keyword>Myocardial ischemia</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>Vascular disease</keyword>
</DOC>